Outcome of Board Meeting

Date: 17.07.2026 Vivimed BSE Limited National Stock Exchange of India Ltd. P.J.Towers, Dalal Street, Exchange Plaza,Plot no. C/1, G Block, Mumbai — 400001 Bandra-Kurla Complex, Bandra (E) BSE - Code : 532660 Mumbai - 400 051 NSE- Symbol: VIVIMEDLAB Dear Sir/Madam Sub: Outcome of Board Meeting- reg. The Suspended Board of Directors & IRP of the Company at its meeting held on July 17, 2026 inter alia, have approved / resolved/ taken note of the following: 1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the audited Financial Results (Standalone & Consolidated) for the quarter and Year ending 31% March , 2026 attached herewith; 2. Auditors’s Report on the audited Financial Results of the Company for the quarter and Year ending 31* March , 2026. The Board Meeting commenced at 14.00 Hrs (IST) and concluded at 16.00 Hrs (IST) Yours faithfully For Vivi anaging Director NOTE - SUSPENSION OF POWERS OF BOARD OF DIRECTORS Pursuant to the commencement of Corporate Insolvency Resolution Process (“CIRP™) under the Insolvency and Bankruptcy Code, 2016, it is hereby informed that the powers of the Board of Directors of Vivimed Labs Limited stand SUSPENDED with effect from the date of commencement of the CIRP, i.e., April 15, 2026. All'powers, functions and duties of the Board of Directors of the Company, as vested under the Companies Act, 2013, the Articles of Association of the Company and all other applicable laws, rules, and regulations, shall henceforth be exercised by the Interim Resolution Professional (IRP) / Resolution Professional (RP), as the case may be, appointed by the Hon’ble National Company Law Tribunal (NCLT). The IRP/RP is now vested with the management and control of the Company and shall exercise all powers that were hitherto vested in the Board of Directors of the Company. No director of the Company shall exercise any of the powers of the Board of Directors during the subsistence of the CIRP. Vivimed Labs Limited. Corporate Office: CIN : L02411KAT988PLC009465 6-3-866/1/G1, 3rd Floor, GMR Towers, Registered Office: #78/A, Kolhar Industrial Area, Greelands, Begumpet, Hyderabad Bidar, Karnataka-585 403, India Telangana-500 016, India. T+91 (0) 8482-232045, F+91 (0( 8482-232436 GSTIN: 36AAACV6060A1ZQ Email: info@vivimedlabs.com | wwwvivimedlabs.com T 91(0) 40-6608-6608, F+91(0) 40-6608-6699 VIVIMED LABS LIMITED. 'AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2026 s n il o Particulars 3Months Ended Year Ended| Year Ended " 31.03.2026| 31.03.2025 55032076 31175075 | 31633035 | 3t0320%6 | S0 Income From Operatons (Audited) | (Unaudited) | (Audited) | (Audited) (Audited) 1 Revenue from Operations mea| wen| asas| swm 103604 Tota evenuefrom operations o[ mem| wmas| e 10308 2{ other income 00 | Cas| sn css 3 Total Revenue (142) 53| tieai| zerar| seess iomss 4| Expenses o costof materal consumed s0s| s | ses o | changeis inventoriesoffinishd goods work nproan gstrocke-ins-Trsace w0 oam| (a2s)| smem (17.86) | employee e Expenses ws| mm| om| w0 ma o Finance coss 751 043 47| sssr 2531 | Deprcistion and Amortsation Expenses wos| wce| acr| s 18631 | otherexpenses so0s7| s | ear| snse 36744 Total Expenses Tas6s7| amior| uiea| 227906 a5 | profc before tax (34) waznon| (eses| (@] g6y (1096) of Tax Expenses - = . - Curten Toxes . : : . Defered Taxes - Totatax expenses - . - - 87|| Ptrohfeirt fCoro tmhpe rpeerihoed n/Ysneaciro v(me5e- 6 ) (1,421.034 ) (165.656 ) (4a.17: )] (1,716.11) (314.9-6 )| Iems thatwil not be recasie toproft o loss, netof ax 020 | oem| e s items that will b rciassfed o profior s, net oftax - - 4 R - Tot other comprehensive ncome [T e G0 5| Totalcomprehinecnomsei (v74e8) G| (esee| es) @0s.17) 10{Paidup quity Share Copital [CET] T T o583 11{0ther equty 12{carings per Shre before Exrsordinary tems) (of Rs2/-each) (o) Basic wi] o s sl (a50) oS(b ) Diluted (16.64)) (1.94) (0.52) (19.98)] 3.69) 1 The Company ha been incuring osses an s net wrth hasbeen eroded. However, he inancil tatements have been prepared on ging concern bass 25 management belees tht the Company will e able to coninue s operatons and meot s ablgations i th foreseeabie foture, ased on ongoie business lans, promoter suppor,and expected mproverments i operatonal performance. 2 The Company is under nvestigaton by the Central Burau of Ivestigtion (CB) pursua f0 a compaint fled by s exender, State Bank of ndi (581, However,ti s stayed by Horrble High Cour of Teangana 3 Corporate Insolvency Resalution Proces (CIRP) On of the vndorsfe an appliaton befre th Horfble NationalCompany Law Tribunal (NCLT. The N, vide ts oder dated 15th Apr 2026, adited] the pettion and ifiatd the Corporate Insclvency Resoltion Proces (CIRP) aganst the Company. Accoringy, an nterm Resauton Prfessona (AP ho] been appoited. The st meetingof the Committe o Crediors (CoC) was hld o 13th May 026. The managerment has extendedfoll oaperation 0 the 1) inthecondofu cIRt proceedings, 4 The tota debt avaled from State Bank o Idis (53 has been asigned to Rare Asset Reconsruction Company Liited (ARC) under the provisios ofthe SARFAESI Act, 2002, Th iabilty continuestoberelcted under “Gorrowings” i the inancial statementsand i ayablto are ARC. 5 One Time Setiement agreement has been entered with Bank of Baharain and Kuvat or 40,05 Milin agans the tota dues of 54895 Milo, Thel upfrnt payment of Rs 0 Milon has been paid 35 per One Time Settement. Howeve, the impact of the TS will e aken i the inancals after e ful payment of OTS i uch time, neres i beingpad b the company: 610 pas,the company has taken ECB loan from IFC amoutin to USD 2.3 miln @602% iterest. The company has negotited with IFC for One Time Settement for USD .80 millon and the same s under pproval process, 7 The company periodical reviews thevalue o tems i inventor ort usabily based on s assessment of market condtons. During the year, Raw Materia| and Packing Matrialprocured could notbe usd due t ackof workingcapital and crtan batches n WIP status were nt complted and had 10 b rejected] and destroyed inaly an due to marketing disuption owing o non payment 0 feldsaf, ishd goods supplied n the market, were nearing t oxpry dte] and have e returned an same were discarde, or resons such s unuitabity of materialqualty and aure oftesting resui, Consequently, venton] amouting o 233,08 milon, primriy pertaiing to Work n Progres, has been writen down t 1t nt realzable vale nd charged 10 the Statement o Profit and Loss, 8 The Company has carried ot the reconciation ofsecuriy deposits and ifeed revenue expenditure as per accounts and based on the reconciaton it idenified that cerai deposis have been recovred and crtan secury deposishave been orfeted by the respectve parties. imiary, i st of Deferted Revenue Expendiure, the balance amount o £209.80 millon out o <3437 millon cauld not be biled. Accordingl, the requred enry. has been passed books of acoudrnitg tshe year 9 In line with provisions of IND-AS 103 Operatig segments, the Company is primarly in Pharma Segment and accordingl the segment reportin is ot applcao bthle company o Compn e et s e R e e e 3D, Place : Hyderabad Date : 17/07/2026 VIVIMED LABS LIMITED AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2026. £ in Milion 3 Months Ended Vear Ended | Vear nded Lo Particlars 31032026 | 3103205 (37.03:2076 | 3112025 [31.03.2025] 51.05.2026 | 31.05.2025 (Auaiteq) |(unaudted) | audited) | (ausited) | _(auaied) Income From Operations 1 Revfreom nopeurateons 12000| 1s989| 2s62s| e9ss| 116269 Totol revenue from aperations 2000 | Toss| 64| 69m | 116269 2| other ncome 5747 ~ | wu| e 71 3| Toto Reven1+e2) 7747|599 | z9831] 763,08 | 120640 4| Expenses o costofmateril consumed 06| mozs| 7s9| a007 s7761 | hanges ininvo efnsnhetd gooodis weorks nprogressondstockin- | 39027 | (1028) 3686| aosa0 2092 | mpioyee seneftExpenses so70| 95| arsr| 2sss 2 [Showing first 8,000 characters — download PDF for full document]